肺栓塞患者中转血栓治疗干预的结果:一个元分析
Muhammad Haisum Maqsood1, Robert S Zhang2, David M Zlotnick3
1Department of Cardiology, DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas, USA.
The Journal of invasive cardiology
|May 22, 2024
概括
在肺栓塞患者中,凝块在运输中的死亡率很高. 系统性血栓缓解药物治疗显示死亡率最低,而单独抗凝剂的死亡率最高,这表明需要进一步研究.
科学领域:
- 心脏病学 心脏病学
- 肺部医学 肺部医学
- 干预性放射学 干预性放射学
背景情况:
- 肺栓塞 (PE) 患者的凝块在运输 (CIT) 与显著的死亡率和糟糕的结果有关.
- 评估PE中CIT不同治疗策略的比较有效性对于临床决策至关重要.
研究的目的:
- 进行一项元分析,评估四种干预措施的CIT和PE患者的聚合死亡率:单抗凝血 (AC) 治疗,全身血栓解压 (ST) 治疗,外科血栓切除术和导管式血栓切除术 (CBT).
主要方法:
- 在PubMed和EMBASE数据库中进行了全面的文献搜索,截至2024年3月28日.
- 包括13项研究 (6项追溯,4项非随机的前性,3项聚合病例报告) 涉及492名CIT和PE患者.
- 每个治疗组的死亡率计算的加权比例.
主要成果:
- 系统性血栓抑制药物治疗显示出最低的加权死亡率 (12%),其次是导管式血栓切除 (20%),手术性血栓切除 (31%) 和单独抗凝药 (35%).
- 单独使用抗凝药与最高的未加权和加权死亡率有关.
- 最常使用的干预措施是全身血栓消毒疗法 (38.2%),其次是外科血栓切除 (33.8%).
结论:
- 系统性血栓缓解药物治疗似乎与CIT和PE患者的最低死亡率有关,而单独抗凝血药物显示的最高死亡率.
- 这些发现凸显了需要强大的随机临床试验数据来最终确定PE中CIT的最佳治疗策略.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
Flail Chest-II
165
Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Assessment:
1. Clinical Evaluation:
History:
165
Clot Retraction and Fibrinolysis
5.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
155
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155
Anticoagulant Drugs: Low-Molecular-Weight Heparins
681
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
681
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
198
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
198


